相似文献
1
Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.构象限制导致一种对结肠炎具有口服活性的选择性CB2大麻素受体激动剂。
ACS Med Chem Lett. 2014 Dec 4;6(2):198-203. doi: 10.1021/ml500439x. eCollection 2015 Feb 12.
2
Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.噻唑和苯并噻唑衍生物作为选择性大麻素 CB2 激动剂的构效关系，具有体内抗炎特性。
Eur J Med Chem. 2019 Oct 15;180:154-170. doi: 10.1016/j.ejmech.2019.07.002. Epub 2019 Jul 2.
3
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1)-one-3-carboxamide scaffold.基于1,8-萘啶-2-(1)-酮-3-甲酰胺支架的选择性荧光大麻素2型受体配体的开发。
Medchemcomm. 2018 Oct 23;9(12):2055-2067. doi: 10.1039/c8md00448j. eCollection 2018 Dec 1.
4
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs.推测的合成大麻素受体激动剂（SCRA）新型精神活性物质（NPS）5F-PY-PICA、5F-PY-PINACA 及其类似物的化学和药理学。
Drug Test Anal. 2019 Jul;11(7):976-989. doi: 10.1002/dta.2583. Epub 2019 May 8.
5
Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.选择性大麻素受体 2 型 (CB2) 激动剂：嘌呤类化合物系列的优化，确定了用于治疗骨关节炎疼痛的临床候选药物。
J Med Chem. 2013 Jul 25;56(14):5722-33. doi: 10.1021/jm400305d. Epub 2013 Jul 3.
6
Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.合成及功能化 6-哌嗪-1-基嘌呤类化合物作为大麻素受体 1（CB1）反向激动剂的药理学特性研究。
Bioorg Med Chem. 2018 Aug 15;26(15):4518-4531. doi: 10.1016/j.bmc.2018.07.043. Epub 2018 Jul 27.
7
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.基于三维定量构效关系分析的大麻素受体 2 高选择性配体的合理设计。
Eur J Med Chem. 2011 Feb;46(2):547-55. doi: 10.1016/j.ejmech.2010.11.034. Epub 2010 Nov 27.
8
Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336.
J Biol Chem. 2006 Sep 22;281(38):28143-51. doi: 10.1074/jbc.M602364200. Epub 2006 Jun 5.
9
10
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.萘-1-基-(4-戊氧基萘-1-基)甲酮（SAB378），一种外周受限的大麻素 CB1/CB2 受体激动剂，抑制胃肠动力，但对小鼠实验性结肠炎没有影响。
J Pharmacol Exp Ther. 2010 Sep 1;334(3):973-80. doi: 10.1124/jpet.110.169946. Epub 2010 Jun 22.
引用本文的文献
1
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.利用定量结构活性关系发现和优化 Tousled 样激酶 2（TLK2）的窄谱抑制剂。
Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357. Epub 2024 Apr 2.
2
Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships.利用定量构效关系发现并优化类酪蛋白激酶2（TLK2）的窄谱抑制剂
bioRxiv. 2023 Dec 28:2023.12.28.573261. doi: 10.1101/2023.12.28.573261.
3
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.内源性大麻素系统作为治疗靶点的利弊：30 年的经验教训。
Pharmacol Rev. 2023 Sep;75(5):885-958. doi: 10.1124/pharmrev.122.000600. Epub 2023 May 10.
4
Rational drug design of CB2 receptor ligands: from 2012 to 2021.CB2受体配体的合理药物设计：2012年至2021年
RSC Adv. 2022 Dec 8;12(54):35242-35259. doi: 10.1039/d2ra05661e. eCollection 2022 Dec 6.
5
Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies.大麻素系统在慢性炎症性肠病中的作用：新疗法的机遇
Intest Res. 2022 Oct;20(4):392-417. doi: 10.5217/ir.2021.00160. Epub 2022 May 31.
6
Endocannabinoids Inhibit the Induction of Virulence in Enteric Pathogens.内源性大麻素抑制肠道病原体毒力的诱导。
Cell. 2020 Oct 29;183(3):650-665.e15. doi: 10.1016/j.cell.2020.09.022. Epub 2020 Oct 7.
7
Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation.靶向 NLRP3 炎性小体治疗炎症性肠病：扑灭炎症之火。
Inflammation. 2019 Aug;42(4):1147-1159. doi: 10.1007/s10753-019-01008-y.
8
Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease?大麻、大麻素和内源性大麻素系统——对炎症性肠病是否有治疗潜力？
J Crohns Colitis. 2019 Mar 30;13(4):525-535. doi: 10.1093/ecco-jcc/jjy185.
9
The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.内源性大麻素系统与心脏病：2型大麻素受体的作用
Cardiovasc Hematol Disord Drug Targets. 2018;18(1):34-51. doi: 10.2174/1871529X18666180206161457.
10
Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease.大麻素受体 2 可改善克罗恩病小鼠模型的炎症。
J Crohns Colitis. 2017 Oct 27;11(11):1369-1380. doi: 10.1093/ecco-jcc/jjx096.
本文引用的文献
1
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.3-羧酰胺-5-芳基异恶唑作为治疗结肠炎的新型 CB2 激动剂。
Bioorg Med Chem. 2013 Sep 1;21(17):5383-94. doi: 10.1016/j.bmc.2013.06.010. Epub 2013 Jun 15.
2
Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features.贝叶斯网络虚拟筛选 CB(2) 受体激动剂和高通量对接：激动剂调节 G 蛋白偶联受体特征的结构见解。
Chem Biol Drug Des. 2013 Apr;81(4):442-54. doi: 10.1111/cbdd.12095.
3
4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.4-氧代-1,4-二氢吡啶作为选择性 CB₂ cannabinoid 受体配体。第 2 部分：发现具有抗实验性结肠炎保护作用的新型激动剂。
J Med Chem. 2012 Oct 25;55(20):8948-52. doi: 10.1021/jm3008568. Epub 2012 Oct 12.
4
The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.炎症性肠病中的内源性大麻素系统：从病理生理学到治疗机会。
Trends Mol Med. 2012 Oct;18(10):615-25. doi: 10.1016/j.molmed.2012.07.009. Epub 2012 Aug 21.
5
Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.大麻素受体 2 (CB2) 激动剂通过抑制 T 细胞的激活并促进其凋亡来改善 IL-10(-/-) 小鼠的结肠炎。
Toxicol Appl Pharmacol. 2012 Jan 15;258(2):256-67. doi: 10.1016/j.taap.2011.11.005. Epub 2011 Nov 18.
6
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.4-氧代-1,4-二氢吡啶作为选择性 CB2 cannabinoid 受体配体：新型反向激动剂系列设计的结构见解。
J Med Chem. 2010 Nov 25;53(22):7918-31. doi: 10.1021/jm100286k. Epub 2010 Oct 27.
7
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.大麻素 2 型受体（CB2）的激活可预防实验性结肠炎。
Inflamm Bowel Dis. 2009 Nov;15(11):1678-85. doi: 10.1002/ibd.20960.
8
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.新型1,8-萘啶和喹啉衍生物作为CB2选择性激动剂。
Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. doi: 10.1016/j.bmcl.2007.09.089. Epub 2007 Oct 1.
9
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.围绕4-氧代-1,4-二氢喹啉-3-甲酰胺类进行的药物调制，一类强效CB2选择性大麻素受体配体：对受体亲和力和功能的影响。
J Med Chem. 2007 Nov 1;50(22):5471-84. doi: 10.1021/jm070387h. Epub 2007 Oct 4.
10
Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.大麻素受体1和2的激动剂可抑制由芥子油和葡聚糖硫酸钠诱导的实验性结肠炎。
Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G364-71. doi: 10.1152/ajpgi.00407.2005. Epub 2006 Mar 30.
Zotero 插件